Known targets — ChEMBL curated mechanism
APH1AAPH1BNCSTNPSEN1PSEN2PSENEN
The experimentally established mechanism targets of Begacestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 known ✓ | P49768 | 5/20 | 1.00 |
| ▸ | PSEN2 known ✓ | P49810 | 5/20 | 1.00 |
| ▸ | APH1B known ✓ | Q8WW43 | 5/20 | 1.00 |
| ▸ | NCSTN known ✓ | Q92542 | 5/20 | 1.00 |
| ▸ | APH1A known ✓ | Q96BI3 | 5/20 | 1.00 |
| ▸ | PSENEN known ✓ | Q9NZ42 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Begacestat SCHEMBL3314371 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Begacestat SCHEMBL2888520 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20877070 | 0.91 | PSEN1 (0.84) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3176071 | 0.87 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13783572 | 0.87 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13431482 | 0.86 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13431483 | 0.86 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4410525 | 0.86 | PSEN1 (0.75) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Sulfuric Acid SCHEMBL4014674 | 0.86 | PSEN1 (0.75) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Sulfuric Acid SCHEMBL4014673 | 0.86 | PSEN1 (0.75) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20230037682-A1 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | NOVARTIS AG (CH) | 2023-02-09 | — | — | US | disclosed |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| US-20220332821-A1 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-20 | — | — | US | disclosed |
| EP-3986569-A1 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | Novartis AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-114286828-A | Dosing regimens and combination therapies for multispecific antibodies targeting B cell maturation antigens | 诺华股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3972634-A2 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| CN-114173810-A | Trispecific binding molecules directed against BCMA and uses thereof | 诺华股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-03 | — | — | US | disclosed |
| CN-112384531-A | Binding molecules against BCMA and uses thereof | 诺华股份有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20200179511-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20200055948-A1 | CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS AG (CH) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332821-A1 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | CD22, CD2, BCL6 | PSEN1 1955/4885PSEN2 3095/4885APH1B 1006/4885 |
| US-20200055948-A1 | CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | BACE1, BACE2, GSAP | PSEN1 33/4885PSEN2 184/4885APH1B 14/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | PSEN1 4521/4885PSEN2 4758/4885APH1B 4252/4885 |
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | CD2, CD4, CD22 | PSEN1 4227/4885PSEN2 4382/4885APH1B 2560/4885 |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | CD2, CD2BP2, CD22 | PSEN1 2781/4885PSEN2 3480/4885APH1B 2992/4885 |
| US-20230037682-A1 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | CD2, CD4, CD14 | PSEN1 3075/4885PSEN2 3436/4885APH1B 2569/4885 |
| US-20200179511-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | BACE1, BACE2, GSAP | PSEN1 6/4885PSEN2 12/4885APH1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.